Prana loss rises to $10m, as R&D spend increases
Thursday, 26 August, 2004
Melbourne brain-disease drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) has reported an after-tax loss of $9.9 million in the year to June.
The loss, up 116 per cent on last year’s result, came despite a 28 per cent lift in revenue, to $2,3 million which included a $1.35 million AusIndustry Start Grant to support the development of the PBT2, Prana’s second-generation lead compound for Alzheimer’s Disease
The biggest contributors to the increased loss were a sharp rise in R&D expenditure, from $1.7 million to $5.3 million and a rise in personnel costs from $1.3 million to $2.7 million.
Prana’s total current assets are valued at $29.7 million up from $3.5 million in 2003. Total non-current assets, including intangibles, were $11.5 million down on last year’s $12.6 million.
The company raised $34.6 million from two share issues, in September 2003, and June this year, resulting in a net increase in cash holdings of $26.3 million.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
